Emcure Pharmaceuticals Limited · NSE:EMCURE

Emcure Pharmaceuticals — Investor Presentation (November 2025)

16 slides from Emcure Pharmaceuticals's investor presentation, Nov 19, 2025

  1. Slide 1: Stock exchange intimation of investor presentation

    Emcure Ref: EPL/CS/SE/0091/2025 Date: November 19, 2025 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear

  2. Slide 2: Investor Presentation November 2025

    Investor Presentation November 2025 1

  3. Slide 3: Disclaimer

    Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and projections about futur

  4. Slide 4: Emcure at a Glance

    Emcure at a Glance INR 7,896Cr 46.3% 11/31 14 FY25 Revenue from FY25 domestic Brand families with Of Top 20 Brands ranked Scale Operations contribution revenue (1) > INR 100/50Cr top 3 in respective TA (1) #2 #13 #8 ~50% Rank by market share in Revenue share from Domestic Rank in Gynaec(1) Largest p

  5. Slide 5: Since IPO, Have Successfully Delivered On…

    Since IPO, Have Successfully Delivered On… Faster than industry growth across markets 1 Margin Expansion Driven by Operating Leverage 2 Robust In-House R&D pipeline Across Key Platforms 3 Several Accretive M&A /Strategic In-Licensing Deals 4 Augmented Domestic Franchise with Experienced Leadership T

  6. Slide 6: Last 6Q, Mid to High Teens Revenue Growth Faster than Industry Growth Across Markets

    Last 6Q, Mid to High Teens Revenue Growth Faster than Industry Growth Across Markets FY25 Grew at 18%+ 1H Delivered 15% Growth 7,896 4,370 6,658 3,817 4,236 2,344 3,660 3,514 1,842 2,026 1,975 3,144 FY24 FY25 FY24 FY25 FY24 FY25 1H FY25 1H FY26 1H FY25 1H FY26 1H FY25 1H FY26 Overall Overall India I

  7. Slide 7: Last 6Q, Operating Margins Expansion

    Last 6Q, Operating Margins Expansion PAT margins up 250bps+ w/ PAT growth of 30%+ EBITDA Margins up 80bp with base margins up 125bp+ PAT Margin improvement of 250bp+ RoCE above 20% 1,200 20.0% 12.0% 19.3% 19.0% 10.7% 22.0% 10.0% 2,000 18.5% 18.6% 1,000 9.0% 18.0% 7.9% 8.0% 19.4% 1,469 800 17.0% 707

  8. Slide 8: Strong global product pipeline of differentiated products to drive growth

    Strong global product pipeline of differentiated products to drive growth Novel Drug Delivery Long Acting Injectables Antibody-Drug Biologics Complex Injectables System (NDDS) (LAI) Conjugates (ADC) Next 24M Med-Long Pipeline Term Pipeline Anti - Diabetes Semaglutide NDDS Ophthalmology Bevacizumab O

  9. Slide 9: Augmented by strategic in-licensing partnerships and acquisitions

    Augmented by strategic in-licensing partnerships and acquisitions In-licensing partnerships Strategic Acquisitions Source: Press Search 1. EP News Bureau 8 2. NDTV

  10. Slide 10: India – Augmented with New Areas, In-Licensing and Experienced Leadership

    India – Augmented with New Areas, In-Licensing and Experienced Leadership DOMESTIC BUSINESS PPM – +16% # Large Brand (1)(2) – 4X Chronic Share(2) up 12% 31 6.6 38.0% 6.3 26.3% Drove Improvements 5.7 in Key Metrics 7 FY24 FY25 H1 FY26 MAT Mar'20 MAT Sep'25 MAT Mar'20 MAT Sep'25 Specialized experience

  11. Slide 11: India – Leadership in Key TAs with strong product pipeline

    India – Leadership in Key TAs with strong product pipeline  R. S. Vasan - 25+ yrs of experience (ex Sun Pharma)  Now 100% subsidiary Key  Focus on Women Health and Cardio-Diabeto – 50% of India sales updates  Seasoned leader 20+ years of experience (ex Sun/Ranbaxy) Brand Revenue Brand Revenue Br

  12. Slide 12: India – Expansion into new therapeutic segments

    India – Expansion into new therapeutic segments A B C Consumer (OTC) Dermatology Super Specialty  $12Bn market growing at 10% CAGR  $1.8+ Bn industry growing at 10%+  Seasoned leader with 20+ years experience with Roche/Novartis  Arth wellness and health supplement  ex-Galderma business leader

  13. Slide 13: Canada – Leadership Position with Long Growth Runway

    Canada – Leadership Position with Long Growth Runway Canada Generic Industry growing at >8%(1) (CAD Bn) Emcure growing significantly faster than industry (INR Cr) 9 8 7 1,252 6 5 923 4 729 690 3 2 1 0 2020 2021 2022 2023 2024 Canada Generic Market (CAD bn) FY23 FY24 FY25 1H26 Significant Room to Gro

  14. Slide 14: Europe – Strong Injectable Portfolio to drive growth

    Europe – Strong Injectable Portfolio to drive growth Europe Generic market is USD70 bn+ market(1) Emcure growing at a significantly pace (INR Cr) 80 1,411 1,474 70 1,187 60 848 50 40 30 20 10 FY23 FY24 FY25 1H26 - 2023 2024 2025  Strong Near term growth drivers – Liposomal Amphotericin B and Manx p

  15. Slide 15: RoW – At an inflection point to achieve exponential growth

    RoW – At an inflection point to achieve exponential growth Strong growth over past few years (INR Cr)  Mix of ARV/Non-ARV business  Strong order book and pipeline of next gen products to 1,510 drive ARV growth 1,181  Non-ARV – At inflection point led by key product 1,033 launches 806  Portfolio

  16. Slide 16: THANK YOU

    THANK YOU For investor relations please contact Investor.Relations@emcure.com Registered Office Address : Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra, India For more information please visit www.emcure.com 15

Emcure Pharmaceuticals — Investor Presentation (November 2025) on 6ix